Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future. Biogen is one of the most popular companies on Eulerpool.com.